- Report
- August 2024
- 200 Pages
Global
From €4344EUR$4,949USD£3,728GBP
- Report
- July 2023
- 82 Pages
Europe
From €1580EUR$1,800USD£1,356GBP
- Report
- July 2023
- 78 Pages
United States
From €1317EUR$1,500USD£1,130GBP
- Report
- July 2023
- 82 Pages
Asia Pacific
From €1580EUR$1,800USD£1,356GBP
- Report
- December 2023
Global
From €2129EUR$2,425USD£1,827GBP
€4257EUR$4,850USD£3,653GBP
- Report
- September 2022
- 182 Pages
Global
From €3906EUR$4,450USD£3,352GBP
- Report
- May 2019
- 83 Pages
Global
From €2853EUR$3,250USD£2,448GBP
The haemostat market is a segment of the wound care industry that focuses on the control of bleeding. Haemostats are products used to stop or slow bleeding from a wound, and can be applied topically or injected into the wound. These products are used in a variety of medical settings, including emergency rooms, operating rooms, and outpatient clinics.
Haemostats are typically made from natural or synthetic materials, such as collagen, fibrin, and thrombin. They are designed to be biocompatible and non-toxic, and can be used to treat a variety of wounds, including cuts, lacerations, and surgical incisions.
The haemostat market is highly competitive, with a number of companies offering a wide range of products. Some of the major players in the market include Johnson & Johnson, Baxter International, C.R. Bard, and Medtronic. Other companies in the market include B. Braun, Integra LifeSciences, and Smith & Nephew. Show Less Read more